Skip to main content

Volume 11 Supplement 1

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

Review

Edited by Josef Smolen

Publication of this supplement has been sponsored by F. Hoffmann-La Roche.

  1. Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, whi...

    Authors: Andrea Rubbert-Roth and Axel Finckh
    Citation: Arthritis Research & Therapy 2009 11(Suppl 1):S1
    Content type: Review Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage 
    3,331,819 downloads
    1,885 Altmetric mentions

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us